A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months (START)

Pharmacology, Toxicology and Pharmaceutical Science

1. Group Trial 100%
2. Placebo 100%
3. Alzheimer's Disease 100%
4. Tolerability 33%
5. Alzheimer's Disease Clinical Trial 33%
6. Diseases 33%